Aim: The aim of this study was to examine the gene frequencies of 16 KIR genes and pseudogenes
Introduction
The Natural killer (NK) cells are a subset of lymphocytes comprising around 10% of total lymphocytes in peripheral blood [1] . Early recognition and killing of virally infected cells and tumour cells are among the most important roles of the NK cells in the innate immunity [2, 3] . The NK cell activity is regulated in activating or inhibiting manner, through specific receptors present on their surface, called killer cell immunoglobulin like receptors (KIRs). The KIRs are encoded by the KIR gene complex, located on chromosome 19, containing a family of polymorphic and highly homologous members (14 genes and 2 pseudogenes), which can be activating or inhibitory [4] . Based on the gene content, two basic KIR haplotypes have been defined, termed A and B. The A haplotype contains a single activating gene, KIR2DS4, which is often present in a deleted (non-expressed) OPEN 
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form, while the B haplotype is more variable and contains many activating genes [5, 6] .
The different KIR haplotypes vary in the number and the type of genes present, but the genes KIR3DL3, KIR3DP1, KIR2DL4 and KIR3DL2 are present on virtually all haplotypes and have therefore been termed framework genes [7] . Population studies performed over the last two decades have revealed extensive diversity at the KIR gene locus, which derives from both, its polygenic and multi-allelic polymorphism, whereas on the basis of gene content, haplotype B displays a much greater variety of subtypes [6, 8] .
The most important for the triggering or inhibition of the NK cells is the balance between the signals generated by the KIRs and their ligands, the HLA molecules [9, 10] . Several recent studies have shown lowered expression of HLA class I molecules in patients with leukaemia [11] [12] [13] To our knowledge, this is the first study of the association of KIR genes with haematological malignant diseases in the Republic of Macedonia.
Material and Methods

Population samples
The study was performed on 63 patients with haematological malignancies hospitalized and treated at the Haematology University Clinic in Skopje, between June, 2001 and September 2009. Distribution according to diagnosis was: acute myeloblastic leukemia 40 (63.5%), chronic myeloid leukemia 11 (17.5%), acute lymphoblastic leukemia 8 (12.7%), non-Hodgkin Lymphoma 2 (3.17%), aplastic anemia 1 (1.59%), and chronic lymphocytic leukemia 1 (1.59%).
KIR genotyping
After signing of written consent, genomic DNA was extracted from the peripheral blood leukocytes using standard phenol/chloroform procedure, described elsewhere [18] , and stored in the Macedonian Human DNA Bank (hDNAMKD) [19] until processing. For KIR genotyping, commercially available PEL-FREEZ KIR genotyping SSP kit (Dynal Biotech, Brown Deer, WI) was used. It is a PCR-based method (using sequencespecific priming approach) designed to detect the presence or absence of 16 KIR genes. The presence of each KIR gene was determined by the presence of a band of DNA of the expected size. All PCRs contained an internal positive control consisting of an additional pair of primers specific for the growth hormone (GH) gene and a negative control. Individuals were determined negative for a particular KIR gene when a band of expected size was absent in the presence of a band for the GH gene. We have used external quality control consisting of cell lines from Immunogenetics and AML, acute myeloblastic leukaemia; CML, chronic myeloid leukaemia; ALL, acute lymphoblastic leukaemia; NHL, non-Hodgkin lymphoma; A. apl., aplastic anemia; CLL, chronic lymphocytic leukemia. 
Statistical analysis
The occurrence of KIR genes in individuals (frequency = F) was obtained by direct counting. Gene frequencies (GF) were calculated using the formula GF=1-√(1-F), being aware of the limitation in its ability to detect KIR genes present at low frequency. For analysis of the molecular polymorphism of the locus studied, the Arlequin software version 3.0 was used. Frequencies for specific genes or genotypes found in the patients group were compared with corresponding frequencies in general Macedonian population, that we have published previously [20] . Comparisons were done using the Fisher's two-sided exact test and Pearson's chisquared test. Risk ratios or crude odds ratios (OR) were calculated within 95% confidence interval. Statistical significance was set to 0.05.
Results
KIR gene frequencies
The KIR gene content and the diagnosis of the 63 Macedonian patients with haematological malignancies are shown in Table 1 .
The frequencies of the 16 KIR genes (14 genes and 2 pseudogenes) determined in the 63 haematological patients along with the corresponding frequencies of the 214 healthy Macedonian controls are shown in Table 2 . All 16 KIR genes were observed in the studied population and framework genes (KIR3DL3, KIR3DP1, KIR2DL4, and KIR3DL2) were present in all individuals, except for three patients who lacked the KIR3DL2 gene.
Comparison of KIR gene frequencies between the 63 patients and healthy Macedonians reveals statistically significant difference for the KIR3DL2 framework gene (F= 1 in the control group, and 0.95 in the patients group, p=0.001). 
Genotype frequencies
Discussion
There are no precise and reliable figures for incidence and survival rates for the different forms of haematological cancer even in highly developed Western European countries and USA. Although the health authorities and their bodies in different regions do publish descriptive statistics, there are many problems with this statistics, such as many cases are never reported to cancer registries, so the actual number of patients could be substantially higher than national figures suggest. Registration figures from United Kingdom for example, suggest around 50 new cases per population of 100,000 [21] , but again, those working in the field believe that this number is considerably higher.
Having in mind the different results regarding the distribution of KIR genes reported in patients with certain forms of haematological cancers [14-17], we have analyzed the KIR genes distribution in Macedonian patients with haematological malignancies and compared them to healthy Macedonians. Although two recent studies reported higher frequency of activating KIR genes, such as KIR2DS1, KIR2DS3 and KIR2DS4 in patients with CML and ALL [22, 23] , we couldn't reproduce these findings in our cohort. Our findings are thus in agreement with those reported from Babor et al, who also found very similar frequencies of KIR genes among haematological patients and healthy controls with European origin [24] . One significant difference that we have observed exclusively in our study was the one involving the frequency of the framework gene KIR3DL2 (Pearson's P= 0.001, after applying Yate's correction P= 0.012). However, comparison of frequencies obtained from larger (or META analysis) series would be needed in order to determine this association as an important protective one in the development of haematological cancers.
As for the comparison of KIR genotype frequencies, we didn't see any significantly different distribution of AA and Bx genotypes between the two groups (P= 0.902). We have observed two statistically significant frequencies for the Bx3 and Bx439 genotypes, both more often present in the patients group (P= 0.019 and P= 0.009, respectively). However, the KIR gene content of the two genotypes is quit different, the former containing all the known KIR genes except KIR2DS3, and the later lacking 6 genes (both inhibitory and activating) (Table 3) , we were not able to draw a conclusion that these might be prototypic KIR genotypes that would increase susceptibility for haematological cancer.
For many of the different forms of haematological cancers, the transplantation of haematopoietic stem cells from bone marrow or peripheral blood either from related or unrelated donors, has become widely recognized as the only curative treatment over the last three decades. Today, it is generally believed that donors containing at most one activating KIR gene should be avoided if possible, because they could more often lead to severe acute GVHD [25 -28] . Our next goal would be to analyze the distribution of KIR genes and the success rate in transplanted pairs of patients with haematological cancer and their corresponding bone marrow donor.
We found that KIR gene frequencies between the total 24 donors and healthy Macedonians reveals statistically significant difference for KIR2DS1 (F= 0.481 in the controls group, and 0.76 in the patients group, p=0.004). This significance is even higher when the frequency of KIR2DS1 in controls is compared with the frequency in donors from pairs with GVHD (F= 0.923, P= 0.002). Another significant difference was observed for the frequency of the full-length allele of KIR2DS4*001-002, present in 25.2% of the control individuals, but in as much as 81.8% of the recipients of HSC (P=0.0005) and suggest that the KIR2DS4*001/002 might be a predisposing factor for severe GVHD in sibling HSCT [29] .
We investigated the role of KIR genes in some viral infections in the Republic of Macedonia. Comparison of KIR gene frequencies between critically ill H1N1/09 Macedonian patients and healthy subjects reveals statistically significant difference for frequency of KIR2DL1 (F=1 in the patients group, and 0.94 in the control group, p=0.045). There is evident predominance of KIR activating genes in the group of patients with severe disease, compared to the healthy controls [30] . Recently we published that comparison of KIR frequencies between Macedonian patients with West Nile virus infection and healthy Macedonian population reveals several significant differences in the inhibitory group (KIR2DL2), and in the non inhibitory group (KIR2DS1, KIR2DS2, KIR2DS5, and KIR3DS1). The single most frequent genotypes in the Bx group were genotypes ID71 and ID89 with statistically significant difference compared to healthy Macedonians. Our results suggest that specific KIR genotypes could be connected with West Nile virus infection [31] .
In conclusion, our results address the distribution of the KIR genes and genotypes in Macedonian patients with haematological cancers. Although we have not determined a certain KIR gene and/or genotype as either predisposing, or protecting factor for haematological malignancy in patients from Republic of Macedonia, we believe that our results could be useful in further (perhaps META) analysis, involving larger series of patients and targeted at the ligands of the KIRs that might suggest involvement of certain combinations of these genes in the development of haematological cancers.
